key: cord-0819194-b3n9vsb9 authors: Pourmoghaddas, Zahra; Sadeghizadeh, Atefeh; Tara, Seyedeh Zahra; Zandifar, Alireza; Rahimi, Hamid; Saleh, Rana; Ghazavi, Mohammadreza; Yaghini, Omid; Hosseini, Neda; Javadi, Niloofar; Saadatnia, Mohammad; Vossough, Arastoo title: Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report date: 2021-08-28 journal: J Neuroimmunol DOI: 10.1016/j.jneuroim.2021.577704 sha: 7b468af52fd6442c48dbd69130f0d53fc3e4c887 doc_id: 819194 cord_uid: b3n9vsb9 COVID-19 infection can cause inflammatory reactions that could involve several organs. In the pediatric population, Multi-System Inflammatory Syndrome in Children (MIS-C) has been reported as one of the consequences of COVID-19. We report a unique pediatric COVID-19 patient with MIS-C, associated with paralysis of the extremities. MRI showed abnormal signal in the cervical spinal cord compatible with transverse myelitis. Methylprednisolone and IVIG were administered, without significant symptom improvement. As a next step, Infliximab was tried for her, and she responded remarkably well to this treatment. Infliximab may be considered as a treatment option in COVID-19 patients with transverse myelitis. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged first in Wuhan, Hubei Province, China in late 2019 and has spread around the world, making it a global health concern (Moriguchi et al., 2020) . Coronavirus disease 2019 (COVID -19) has been mostly recognized with its respiratory symptoms, such as cough and dyspnea (Zimmermann and Curtis, 2020) Transverse myelitis (TM) is an acute or subacute inflammatory myelopathy, which can result in motor, sensory, and autonomic dysfunction (West, 2013) . A few cases of TM as a post-COVID-19 complication have been reported, but details of treatment have not been described in the majority of the pediatric cases as the reports were predominantly focused on imaging (Baghbanian and Namazi, 2020; Nevertheless, no consensus has been established for the treatment of this complication yet and the treatments reported in previous cases have not had a good prognosis. In this article, we report a child with longitudinally extensive transverse myelitis (LETM) who had a favorable response to Infliximab therapy in addition to routine management. A 9-year-old female presented with fever and progressive paralysis of all four limbs after falling while playing. She was suspected to only have a mild trauma to the neck, and the timing of J o u r n a l P r e -p r o o f Journal Pre-proof symptom onset and progression was not compatible with the traumatic accident (>24 hours after trauma). She was admitted to the emergency department (ED) six days after symptoms initiation. Upon admission, a nasopharyngeal swab test was performed due to fever and SARS-CoV-2 was detected via PCR assay. In the ED, the patient and her parents did not report any recent upper respiratory infection Five days after admission, the patient started to have palmar rash, which was self-limited. During the seventh day of hospitalization, she experienced hypotension which was managed by norepinephrine. One day after receiving norepinephrine, she started having a severe headache. Brain CT was performed, which was normal. Her plasmapheresis plan also did not proceed due to hemodynamic instability. Laboratory data demonstrated elevated ferritin levels (table 1). Two doses (5 mg/kg) of Infliximab were administered on the tenth and twenty-second days of admission, while calcium gluconate and norepinephrine were put on hold until day sixteen. Following these steps, her symptoms improved, with her right upper and left lower limb strength increasing to 3/5 and the left upper and right lower limb increasing to 4/5. Her blood pressure stabilized and gradually improved. another study used Rituximab after remission of acute TM and did not report the outcome of Rituximab injection (Kaur et al., 2020) . In addition, one study reported positive effects of Infliximab on radiotherapy-induced TM (Chang et al., 2018) . To the best of our knowledge, this case study is the first pediatric case of concomitant TM and COVID-19, who responded well to empirical Infliximab therapy. Bradycardia in Patients With COVID-19: A Calm Before the Storm? Cureus 12 Central nervous system manifestations of COVID-19: A systematic review COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics Post COVID-19 longitudinally extensive transverse myelitis (LETM)-a case report COVID-19-associated acute transverse myelitis: a rare entity Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation Acute transverse myelitis in COVID-19 infection A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) | CDC [WWW Document Transverse Myelitis in a Child With COVID-19 Viral myelitis: an update ASPNR PECOBIG Collaborator Group, n.d. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study Myelopathy associated with microorganisms A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Cardiovascular impairment in a patient with acute myelitis A case report of acute transverse myelitis following novel coronavirus infection Proposed diagnostic criteria and nosology of acute transverse myelitis Acute transverse myelitis associated with SARS-CoV-2: A Case-Report Transverse myelitis--a review of the presentation, diagnosis, and initial management Neurological Manifestations of COVID-19: A systematic review and current update Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children